Title |
New therapeutic targets in the management of urothelial carcinoma of the bladder
|
---|---|
Published in |
Research and Reports in Urology, March 2013
|
DOI | 10.2147/rru.s29131 |
Pubmed ID | |
Authors |
Einar F Sverrisson, Patrick N Espiritu, Philippe E Spiess |
Abstract |
Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern urological clinical practice. New therapies target biomolecular pathways and cellular mediators responsible for regulating cell growth and metabolism, both of which are frequently overexpressed in malignant urothelial cells, with the intent of inducing cell death by limiting cellular metabolism and growth, creating an immune response, or selectively delivering or activating a cytotoxic agent. These new and novel therapies may offer a potential for reduced toxicity and an encouraging hope for better treatment outcomes, particularly for a disease often refractory or not amenable to the current therapeutic approaches. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 7 | 20% |
Researcher | 6 | 17% |
Student > Master | 5 | 14% |
Student > Bachelor | 3 | 9% |
Student > Doctoral Student | 2 | 6% |
Other | 6 | 17% |
Unknown | 6 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 46% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
Biochemistry, Genetics and Molecular Biology | 2 | 6% |
Agricultural and Biological Sciences | 2 | 6% |
Social Sciences | 1 | 3% |
Other | 3 | 9% |
Unknown | 7 | 20% |